Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Cibotercept
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. Cibotercept appears in 1 tracked Healthcare story from March 4, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Cibotercept. Shared-story counts are live from our verified record — not editorial picks.
Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.